CD274 and colorectal carcinoma: In clinical trials of treating CRC with PD-L1 in combination with CTLA-4, higher TMB was associated with better OS, so stratification of patients by immune mutational load prior to treatment may help determine patient treatment efficacy and thus contribute to the selection of therapeutic agents.